The Selling of Attention Deficit Disorder

1/6/2014

This article from The New York Times investigates the rising rates of diagnosis and medication for Attention Deficit Hyperactivity Disorder (ADHD) in America. It explores the complex factors behind the surge, including pharmaceutical marketing, increased awareness, and changes in diagnostic criteria. The article highlights the influence of drug companies in promoting and expanding the definition of ADHD, leading to concerns about overdiagnosis and overmedication. It also discusses the potential consequences and ethical implications of pathologizing normal childhood behaviors. Overall, the article delves into the commercialization of ADHD and its impact on the mental health industry.

attention deficit disorder ꞏ adhd ꞏ pharmaceutical industry ꞏ overdiagnosis ꞏ overmedication ꞏ children's health ꞏ mental health ꞏ behavioral disorders ꞏ medication ꞏ marketing ꞏ healthcare system ꞏ prescription drugs ꞏ stimulant medication ꞏ psychiatric disorders ꞏ drug industry ꞏ diagnosing adhd ꞏ psychoactive drugs ꞏ psychotropic medication ꞏ medicalization of childhood ꞏ school performance ꞏ children's behavior ꞏ drug advertising ꞏ mental health treatment ꞏ psychological well-being ꞏ child psychology ꞏ behavioral interventions ꞏ neurobehavioral disorders ꞏ stimulant use ꞏ psychiatric medications ꞏ parental concerns ꞏ educational system ꞏ healthcare policy ꞏ medical ethics ꞏ mental health stigma ꞏ treatment alternatives ꞏ holistic approach ꞏ societal impact ꞏ long-term effects ꞏ academic performance ꞏ social dynamics ꞏ public health ꞏ healthcare reform ꞏ mental health diagnosis ꞏ behavioral healthcare ꞏ psychological interventions ꞏ pharmaceutical marketing ꞏ attention disorders